"treatment_id","first_author","doi","commercial_affiliation","publication_date","journal","study_type","gender_ratio","dose_range","race_ethnicity","notes"
"1","Amatachaya, Anuwat","10.1155/2014/173073","No conflicts of interest. ","October 2014","Behavioural Neurology","Randomized Double-blind Placebo Controlled ","100% M","1mA anodal tDCS targeting left dorsolateral prefrontal cortex (DLPFC), or sham (placebo) tDCS","Not reported","Results of this study are not explained very clearly. "
"2","Veenstra-VanderWeele, Jeremy","10.1038/npp.2016.237","Seaside Therapeutics, Roche, Novartis, SynapDx, Forest, Springer and wiley. ","November 9, 2016","Neuropsychopharmacology","Randomized Double-blind Placebo Controlled  ","124 M: 26 F","","96 White Non-Hispanic; 19 White Hispanic; 17 African American; 8 Asian; 10 Other",""
"3","Delahunty, C","","","2013","American Academy of Pediatrics","RCT - Phase 2","124 M: 26 F","max: 10 mg 3x/d for 5-11y, 15 mg 3x/d for 12-21 y","",""
"4","Delahunty, C","","","2013","American Academy of Pediatrics","RCT - Phase 2","124 M: 26 F","max: 10 mg 3x/d for 5-11y, 15 mg 3x/d for 12-21 y","",""
"3","Berry-Kravis, EM","10.1126/scitranslmed.3004214","No conflicts of interest","2012","Science Translational Medicine","Randomized Double-blind Placebo Controlled  - Pilot","55 M: 8 F","max: 10 mg BID for children, 10 mg 3x/d for adults","",""
"4","Berry-Kravis, EM","10.1126/scitranslmed.3004214","No conflicts of interest","2012","Science Translational Medicine","Randomized Double-blind Placebo Controlled  - Pilot","55 M: 8 F","max: 10 mg BID for children, 10 mg 3x/d for adults","",""
"5","Ichikawa, Hironobu","10.1007/s10578-016-0704-x","3 authors are Employees of Otsuka Pharmaceutical Co. ","December 21, 2016","Child Psychiatry and Human Development","Randomized Double-blind Placebo Controlled  ","17 F: 75 M","1-15 mg/d; Mean: 8.1 mg/d (SD: 2.0)","Conducted with 'specific populations considering influence of genetic/physiologic variation and/or cultural environmental difference on treatment variable'. ","This study was conducted to test the effects of aripiprazole treatment in Japanese children, as all studies of this drug had used primarily caucasion populations in the U.S. "
"6","Ichikawa, Hironobu","10.1007/s10578-016-0704-x","3 authors are Employees of Otsuka Pharmaceutical Co. ","December 21, 2016","Child Psychiatry and Human Development","Randomized Double-blind Placebo Controlled  ","17 F: 75 M","1-15 mg/d; Mean: 8.1 mg/d (SD: 2.0)","Conducted with 'specific populations considering influence of genetic/physiologic variation and/or cultural environmental difference on treatment variable'. ","This study was conducted to test the effects of aripiprazole treatment in Japanese children, as all studies of this drug had used primarily caucasion populations in the U.S. "
"7","Ichikawa, Hironobu","10.1007/s10578-016-0704-x","3 authors are Employees of Otsuka Pharmaceutical Co. ","December 21, 2016","Child Psychiatry and Human Development","Randomized Double-blind Placebo Controlled  ","17 F: 75 M","1-15 mg/d; Mean: 8.1 mg/d (SD: 2.0)","Conducted with 'specific populations considering influence of genetic/physiologic variation and/or cultural environmental difference on treatment variable'. ","This study was conducted to test the effects of aripiprazole treatment in Japanese children, as all studies of this drug had used primarily caucasion populations in the U.S. "
"8","Ichikawa, Hironobu","10.1007/s10578-016-0704-x","3 authors are Employees of Otsuka Pharmaceutical Co. ","December 21, 2016","Child Psychiatry and Human Development","Randomized Double-blind Placebo Controlled  ","17 F: 75 M","1-15 mg/d; Mean: 8.1 mg/d (SD: 2.0)","Conducted with 'specific populations considering influence of genetic/physiologic variation and/or cultural environmental difference on treatment variable'. ","This study was conducted to test the effects of aripiprazole treatment in Japanese children, as all studies of this drug had used primarily caucasion populations in the U.S. "
"5","Findling, Robert","","Conflicts of interest. Affiliations with: Kennedy Krieger Institute, Johns Hopkins University, Bristol-Meyers Squibb (9/10 Authors), Otsuka Pharmaceutical Co, Genzyme Corp","January 2014","Journal of Clinical Psychiatry","Randomized placebo controlled relapse prevention trial","17 F: 68 M","2-15 mg/d, flexible dose; Mean dose: ","69.4% white; 22.4% black;                           3% Asian; 1% American Indian/Alaska Native;                                        13% other","9/10 authors associated with Otsuka Pharmaceuticals and Bristol-Myers Squibb, both of which are primary shareholders in Abilify. "
"6","Findling, Robert","","Conflicts of interest. Affiliations with: Kennedy Krieger Institute, Johns Hopkins University, Bristol-Meyers Squibb (9/10 Authors), Otsuka Pharmaceutical Co, Genzyme Corp","January 2014","Journal of Clinical Psychiatry","Randomized placebo controlled relapse prevention trial","17 F: 68 M","2-15 mg/d, flexible dose; Mean dose: ","69.4% white; 22.4% black;                           3% Asian; 1% American Indian/Alaska Native;                                        13% other","9/10 authors associated with Otsuka Pharmaceuticals and Bristol-Myers Squibb, both of which are primary shareholders in Abilify. "
"7","Findling, Robert","","Conflicts of interest. Affiliations with: Kennedy Krieger Institute, Johns Hopkins University, Bristol-Meyers Squibb (9/10 Authors), Otsuka Pharmaceutical Co, Genzyme Corp","January 2014","Journal of Clinical Psychiatry","Randomized placebo controlled relapse prevention trial","17 F: 68 M","2-15 mg/d, flexible dose; Mean dose: ","69.4% white; 22.4% black;                           3% Asian; 1% American Indian/Alaska Native;                                        13% other","9/10 authors associated with Otsuka Pharmaceuticals and Bristol-Myers Squibb, both of which are primary shareholders in Abilify. "
"8","Findling, Robert","","Conflicts of interest. Affiliations with: Kennedy Krieger Institute, Johns Hopkins University, Bristol-Meyers Squibb (9/10 Authors), Otsuka Pharmaceutical Co, Genzyme Corp","January 2014","Journal of Clinical Psychiatry","Randomized placebo controlled relapse prevention trial","17 F: 68 M","2-15 mg/d, flexible dose; Mean dose: ","69.4% white; 22.4% black;                           3% Asian; 1% American Indian/Alaska Native;                                        13% other","9/10 authors associated with Otsuka Pharmaceuticals and Bristol-Myers Squibb, both of which are primary shareholders in Abilify. "
"5","Marcus, Ronald N. ","","Several authors are affiliated with Otsuka Pharmaceutical Development and Bristol-Myers Squibb. ","November 2009","The American Journal of Child Adolescent Psychiatry","RPCT Fixed-Dose l ","195 M","5, 10, or 15 mg/d","155 White; 50 Black; 6 Asian; 7 Other",""
"6","Marcus, Ronald N. ","","Several authors are affiliated with Otsuka Pharmaceutical Development and Bristol-Myers Squibb. ","November 2009","The American Journal of Child Adolescent Psychiatry","RPCT Fixed-Dose l ","195 M","5, 10, or 15 mg/d","155 White; 50 Black; 6 Asian; 7 Other",""
"7","Marcus, Ronald N. ","","Several authors are affiliated with Otsuka Pharmaceutical Development and Bristol-Myers Squibb. ","November 2009","The American Journal of Child Adolescent Psychiatry","RPCT Fixed-Dose l ","195 M","5, 10, or 15 mg/d","155 White; 50 Black; 6 Asian; 7 Other",""
"8","Marcus, Ronald N. ","","Several authors are affiliated with Otsuka Pharmaceutical Development and Bristol-Myers Squibb. ","November 2009","The American Journal of Child Adolescent Psychiatry","RPCT Fixed-Dose l ","195 M","5, 10, or 15 mg/d","155 White; 50 Black; 6 Asian; 7 Other",""
"5","Owen, Randall","10.1542/peds.2008-3782","Funding provided by Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co. ","December 2009","American Academy of Pediatrics","Randomized Double-blind Placebo Controlled  ","86 M: 12 F","Flexible dose: 5, 10, or 15 mg/d","73 White; 18 Black; 2 Asian; 5 Other","Bristol-Myers Squibb Company paid over $515 million to the U.S. government to resolve fraudulent marketing and pricing schemes.  This settlement included 7 qui tam actions. The FDA mandated that the package for Abilify carry a ""black box"" warning for use with dementia-related psychosis. BMS knowingly promoted the same and use of Abilify for pediatric use and to treat demntia-related psychosis.  https://www.justice.gov/archive/opa/pr/2007/September/07_civ_782.html"
"6","Owen, Randall","10.1542/peds.2008-3782","Funding provided by Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co. ","December 2009","American Academy of Pediatrics","Randomized Double-blind Placebo Controlled  ","86 M: 12 F","Flexible dose: 5, 10, or 15 mg/d","73 White; 18 Black; 2 Asian; 5 Other","Bristol-Myers Squibb Company paid over $515 million to the U.S. government to resolve fraudulent marketing and pricing schemes.  This settlement included 7 qui tam actions. The FDA mandated that the package for Abilify carry a ""black box"" warning for use with dementia-related psychosis. BMS knowingly promoted the same and use of Abilify for pediatric use and to treat demntia-related psychosis.  https://www.justice.gov/archive/opa/pr/2007/September/07_civ_782.html"
"7","Owen, Randall","10.1542/peds.2008-3782","Funding provided by Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co. ","December 2009","American Academy of Pediatrics","Randomized Double-blind Placebo Controlled  ","86 M: 12 F","Flexible dose: 5, 10, or 15 mg/d","73 White; 18 Black; 2 Asian; 5 Other","Bristol-Myers Squibb Company paid over $515 million to the U.S. government to resolve fraudulent marketing and pricing schemes.  This settlement included 7 qui tam actions. The FDA mandated that the package for Abilify carry a ""black box"" warning for use with dementia-related psychosis. BMS knowingly promoted the same and use of Abilify for pediatric use and to treat demntia-related psychosis.  https://www.justice.gov/archive/opa/pr/2007/September/07_civ_782.html"
"8","Owen, Randall","10.1542/peds.2008-3782","Funding provided by Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co. ","December 2009","American Academy of Pediatrics","Randomized Double-blind Placebo Controlled  ","86 M: 12 F","Flexible dose: 5, 10, or 15 mg/d","73 White; 18 Black; 2 Asian; 5 Other","Bristol-Myers Squibb Company paid over $515 million to the U.S. government to resolve fraudulent marketing and pricing schemes.  This settlement included 7 qui tam actions. The FDA mandated that the package for Abilify carry a ""black box"" warning for use with dementia-related psychosis. BMS knowingly promoted the same and use of Abilify for pediatric use and to treat demntia-related psychosis.  https://www.justice.gov/archive/opa/pr/2007/September/07_civ_782.html"
"9","Ghanizadeh, Ahmed","","No conflicts of interest. ","June 26, 2013","Child Psychiatry and Human Development","Randomized Double-blind Placebo Controlled ; head to head comparison","48 M: 11 F","Aripiprazole mean: 5.5 mg/d; Risperidone mean: 1.12 mg/d. Max dose for aripiprazole was 15 mg/d and 3 mg/d for risperidone. ","""No stratification considering factors, such as age, gender, diagnoses was conducted."" ","The dosage was flexible based on efficacy in the individual subjects. Aripiprazole and risperidone are the only FDA approved medications for treating maladaptive behaviors in autism. "
"10","DeVane, C.","10.1002/phar.2271","No conflicts of interest. ","June 2019","Pharmacotherapy","randomized double-blind parallel-group","48 M: 13 F","aripiprazole: 2-15 mg/d; risperidone: 0.5-3.0 mg/d","38 white; 19 black; 2 mixed (white/black); 1 mixed (white/Native American); 1 Asian","Biomarkers in Autism of Aripiprazole and Risperdione Treatment (BAART)"
"11","Harfterkamp, Myriam ","","No conflicts of interest reported. ","July 1, 2012","Child and Adolescent Psychiatry","Randomized Double-blind Placebo Controlled  ","","1.2 mg/dk/d","","Could only access the abstract, will add the last bits of information when accessed. "
"12","Harfterkamp, Myriam ","","No conflicts of interest reported. ","July 1, 2012","Child and Adolescent Psychiatry","Randomized Double-blind Placebo Controlled  ","","1.2 mg/dk/d","","Could only access the abstract, will add the last bits of information when accessed. "
"13","Harfterkamp, Myriam ","","No conflicts of interest reported. ","July 1, 2012","Child and Adolescent Psychiatry","Randomized Double-blind Placebo Controlled  ","","1.2 mg/dk/d","","Could only access the abstract, will add the last bits of information when accessed. "
"11","Harfterkamp, Myriam","","","May 28, 2012","Journal of the American Academy of Child and Adolescent Psychiatry ","Randomized Double-blind Placebo Controlled ","","1.2 mg/kg/d","","Trial for patients with ADHD and ASD (comorbid). https://www.jaacap.org/article/S0890-8567(12)00307-3/fulltext"
"12","Harfterkamp, Myriam","","","May 28, 2012","Journal of the American Academy of Child and Adolescent Psychiatry ","Randomized Double-blind Placebo Controlled ","","1.2 mg/kg/d","","Trial for patients with ADHD and ASD (comorbid). https://www.jaacap.org/article/S0890-8567(12)00307-3/fulltext"
"13","Harfterkamp, Myriam","","","May 28, 2012","Journal of the American Academy of Child and Adolescent Psychiatry ","Randomized Double-blind Placebo Controlled ","","1.2 mg/kg/d","","Trial for patients with ADHD and ASD (comorbid). https://www.jaacap.org/article/S0890-8567(12)00307-3/fulltext"
"11","Handen, Benjamin","","","September 2, 2015","Journal of the American Academy of Child and Adolescent Psychiatry ","Randomized, Double-blind, 2x2 trial of ATX and Parent Training, Placebo Controlled ","","max: 1.8 mg/kg/d","",""
"12","Handen, Benjamin","","","September 2, 2015","Journal of the American Academy of Child and Adolescent Psychiatry ","Randomized, Double-blind, 2x2 trial of ATX and Parent Training, Placebo Controlled ","","max: 1.8 mg/kg/d","",""
"13","Handen, Benjamin","","","September 2, 2015","Journal of the American Academy of Child and Adolescent Psychiatry ","Randomized, Double-blind, 2x2 trial of ATX and Parent Training, Placebo Controlled ","","max: 1.8 mg/kg/d","",""
"14","Mahdavinsasab, Seyedeh-Mahsa","","No conflicts of interest reported. ","April 12, 2019","European Child & Adolescent Psychiatry","Randomized Double-blind Placebo Controlled  ","46 M: 18 F","Baclofen: 0.6 mg Kg^-1 3x/day; Max dose of Risperidone was 1 mg/d for pts under 20kg and 2 mg/d for pts 20 kgo","Not reported. ","""TheA35:V35 present randomized-controlled trial provided the first clinical evidence of safety and efficacy of baclofen as an adjuvant to risperidone to improve hyperactivity symptoms in children with ASD."" There have been multiple trials with Baclofen in mice. As we"
"15","Mahdavinsasab, Seyedeh-Mahsa","","No conflicts of interest reported. ","April 12, 2019","European Child & Adolescent Psychiatry","Randomized Double-blind Placebo Controlled  ","46 M: 18 F","Baclofen: 0.6 mg Kg^-1 3x/day; Max dose of Risperidone was 1 mg/d for pts under 20kg and 2 mg/d for pts 20 kgo","Not reported. ","""TheA35:V35 present randomized-controlled trial provided the first clinical evidence of safety and efficacy of baclofen as an adjuvant to risperidone to improve hyperactivity symptoms in children with ASD."" There have been multiple trials with Baclofen in mice. As we"
"14","Mahdavinsasab, Seyedeh-Mahsa","10.1007/s00787-019-01333-5","No conflicts of interest reported. ","April 2019","European Child & Adolescent Psychiatry","Randomized Double-blind Placebo Controlled  ","46 M: 18 F","Baclofen: 0.6mg Kg^-1 3x/day; Max dose of Risperidone was 1mg/day for pts under 20kg and 2mg/day for pts 20kg and over","Not reported. ","""TheA35:V35 present randomized-controlled trial provided the first clinical evidence of safety and efficacy of baclofen as an adjuvant to risperidone to improve hyperactivity symptoms in children with ASD."" There have been multiple trials with Baclofen in mice. As we"
"15","Mahdavinsasab, Seyedeh-Mahsa","10.1007/s00787-019-01333-5","No conflicts of interest reported. ","April 2019","European Child & Adolescent Psychiatry","Randomized Double-blind Placebo Controlled  ","46 M: 18 F","Baclofen: 0.6mg Kg^-1 3x/day; Max dose of Risperidone was 1mg/day for pts under 20kg and 2mg/day for pts 20kg and over","Not reported. ","""TheA35:V35 present randomized-controlled trial provided the first clinical evidence of safety and efficacy of baclofen as an adjuvant to risperidone to improve hyperactivity symptoms in children with ASD."" There have been multiple trials with Baclofen in mice. As we"
"16","Hollander, E","10.1001/jamapsychiatry.2022.1717","Hoffman-La Roche Ltd.","July 2022","JAMA Psychiatry","RCT","139 M: 28 F","4 mg or 10 mg","133 white; 10 Asian; 8 black/African American; 1 Pacific Islander; 13 multiple; 2 unknown",""
"17","Lemonnier, E","10.1038/tp.2012.124","No conflicts of interest. ","December 11, 2012","Translational Psychiatry ","Randomized Double-blind Placebo Controlled  ","89% M; 11% F","0.5 mg BID","not reported",""
"18","Lemonnier, E","10.1038/tp.2012.124","No conflicts of interest. ","December 11, 2012","Translational Psychiatry ","Randomized Double-blind Placebo Controlled  ","89% M; 11% F","0.5 mg BID","not reported",""
"19","Lemonnier, E","10.1038/tp.2012.124","No conflicts of interest. ","December 11, 2012","Translational Psychiatry ","Randomized Double-blind Placebo Controlled  ","89% M; 11% F","0.5 mg BID","not reported",""
"17","Dai, Yuan","https://doi.org/10.1016/j.scib.2021.01.008","No conflicts of interest","Dec-20","Science Bulletin","RCT","19 F: 100 M","0.5 mg BID","not reported",""
"18","Dai, Yuan","https://doi.org/10.1016/j.scib.2021.01.008","No conflicts of interest","Dec-20","Science Bulletin","RCT","19 F: 100 M","0.5 mg BID","not reported",""
"19","Dai, Yuan","https://doi.org/10.1016/j.scib.2021.01.008","No conflicts of interest","Dec-20","Science Bulletin","RCT","19 F: 100 M","0.5 mg BID","not reported",""
"17","Sprengers, Jan","10.1016/j.jaac.2020.07.888","ZonMW, NOW, Aspect Neuroprofiles BC","July 2020","Journal of the American Academy of Child & Adolescent Psychiatry","Randomized Double-blind Placebo Controlled ","63 M: 29 F","0.03 mg/kg BID for <30kg; 1.0 mg BID for 30 kgo - participants supplemented with potassium chloride: 0.5 mmol/kg if <30kg, or 8 mmol BID if 30 kgo","not reported",""
"18","Sprengers, Jan","10.1016/j.jaac.2020.07.888","ZonMW, NOW, Aspect Neuroprofiles BC","July 2020","Journal of the American Academy of Child & Adolescent Psychiatry","Randomized Double-blind Placebo Controlled ","63 M: 29 F","0.03 mg/kg BID for <30kg; 1.0 mg BID for 30 kgo - participants supplemented with potassium chloride: 0.5 mmol/kg if <30kg, or 8 mmol BID if 30 kgo","not reported",""
"19","Sprengers, Jan","10.1016/j.jaac.2020.07.888","ZonMW, NOW, Aspect Neuroprofiles BC","July 2020","Journal of the American Academy of Child & Adolescent Psychiatry","Randomized Double-blind Placebo Controlled ","63 M: 29 F","0.03 mg/kg BID for <30kg; 1.0 mg BID for 30 kgo - participants supplemented with potassium chloride: 0.5 mmol/kg if <30kg, or 8 mmol BID if 30 kgo","not reported",""
"20","Ghanizadeh, Ahmed","https://doi.org/10.1016/j.pediatrneurol.2014.09.017","","October 2014","Pediatric Neurology","RCT","","mean: 6.7 mg/d (SD 2.7)","",""
"21","Chugani, Diane","","No conflicts of interest. ","March 2016","The Journal of Pediatrics","Randomized Double-blind Placebo Controlled  ","29 F: 137 M","Placebo; 2.5mg (n=54) po BID; 5.0mg po BID (n=55) ","1% American Indian/Alaska Native; 1% Asian; 31% Black/African American; 2% Hawaiian; 58% White; 7% Other","This trial supports that lower dosage of buspirone could be more beneficial than higher doses in improving social competency, and reducing restrictive and repetitive behaviors in children with ASD."
"22","Aran, Adi","10.1186/s13229-021-00420-2","BOL Pharma (Aran and Castellanos)","2021","Molecular Autism","Randomized Double-blind Placebo Controlled   - Crossover","80% M: 20% F","20-40 kg: 1 mg/kg/d CBD and 0.5 mg/kg/d THC; 40 kgo: 7.5 mg/kg/d CBD and 0.375 mg/kd/d THC","not reported",""
"23","Asadabadi, Mahtab","https://doi.org/10.1007/s00213-012-2796-8","No conflicts of interest","July 2012","Psychopharmacology","RCT","25 M: 15 F","risperidone max: 3 mg/d; celecoxib max: 300 mg/d","Not reported. ",""
"24","King, Bryan","","National Institutes of Health, BioMarin, Neuropharm, Forest Labratories, Nastech, and Seaside Therapeutics, Bristol-Meyers Squibb, Abbott Labs, UCB Pharma, Shire, Pfizer, Johnson & Johnson","June 2009","Arch Gen Psychiatry","Randomized Double-blind Placebo Controlled  ","128 M: 21 F","10 mg/5mL; mean: 6.5 mg/d","108 White; 17 Black; 1 Native Hawaiian; 2 American Indian/Alaska Native; 10 Other","Lack of efficacy of Citalopram in treatment of bx in ASD."
"25","Munasinghe, Sujeeva","","The authors did not state conflicts or interest, nor no conflicts of interest.","March 2010","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled  - Crossover","21 M (seq 1), 22 M (seq 2)","2 capsules with each meal (1 capsule recommended to be given with snacks containing gluten or casein)","not reported",""
"26","Hollander, Eric","10.1038/npp.2009.202","Consultation fees from Abbott, neuropharm, Nastech, BMS, and Forest. Hollander has intellectual property related to oxytocin and memantine. InteGragen, and USB Pharma. ","December 9, 2009","Neuropsychopharmacology","Randomized Double-blind Placebo Controlled  ","23 M: 4 F","Titrated up according to body weight. Minimum level was 50ug/ml. 125mg po QH5-250mg po BID for <40kg. 250 mg po QHS-500mg po BID for >40kg","8 White non-hispanic; 6 Hispanic; 6 Black; 3 Asian; 2 Other; 2 More than one race",""
"27","Chez, MG","","","2003","Journal of Pediatric Neurology","Randomized Double-blind Placebo Controlled ","","","",""
"28","Chez, MG","","","2003","Journal of Pediatric Neurology","Randomized Double-blind Placebo Controlled ","","","",""
"27","Handen, BL","","","2011","Journal of Adolescent Psychopharmacology","Randomized Double-blind Placebo Controlled ","","5-10 mg/d","",""
"28","Handen, BL","","","2011","Journal of Adolescent Psychopharmacology","Randomized Double-blind Placebo Controlled ","","5-10 mg/d","",""
"29","Leventhal, BL","10.1176/jnp.5.3.307","","1993","The Journal of Neuropsychiatry and Clinical Neurosciences","double-blind placebo-controlled crossover trial","","60 mg/d","","https://europepmc.org/article/med/8369641"
"30","Leventhal, BL","10.1176/jnp.5.3.307","","1993","The Journal of Neuropsychiatry and Clinical Neurosciences","double-blind placebo-controlled crossover trial","","60 mg/d","","https://europepmc.org/article/med/8369641"
"29","Barthelemy, C.","","","June 1989","Journal of Autism & Developmental Disorders","","","1.5 mg/kg/d ","",""
"30","Barthelemy, C.","","","June 1989","Journal of Autism & Developmental Disorders","","","1.5 mg/kg/d ","",""
"31","Hollander, Eric","","Two authors consulted for Neuropharm. Dr. Hollander has consulted for Abbott and Forest Dr. Anagnostou has consulted to Novartis and Proximagen. ","March 2012","The American Journal of Psychiatry  ","Randomized Double-blind Placebo Controlled ","26 M: 11 F","20-80 mg/d; mean: 64.76 mg/d","73% White; 11% Black; 3% Asian; 5% Hispanic; 8% Other ",""
"32","Hollander, Eric","","Two authors consulted for Neuropharm. Dr. Hollander has consulted for Abbott and Forest Dr. Anagnostou has consulted to Novartis and Proximagen. ","March 2012","The American Journal of Psychiatry  ","Randomized Double-blind Placebo Controlled ","26 M: 11 F","20-80 mg/d; mean: 64.76 mg/d","73% White; 11% Black; 3% Asian; 5% Hispanic; 8% Other ",""
"33","Hollander, Eric","","Two authors consulted for Neuropharm. Dr. Hollander has consulted for Abbott and Forest Dr. Anagnostou has consulted to Novartis and Proximagen. ","March 2012","The American Journal of Psychiatry  ","Randomized Double-blind Placebo Controlled ","26 M: 11 F","20-80 mg/d; mean: 64.76 mg/d","73% White; 11% Black; 3% Asian; 5% Hispanic; 8% Other ",""
"34","Hollander, Eric","","Two authors consulted for Neuropharm. Dr. Hollander has consulted for Abbott and Forest Dr. Anagnostou has consulted to Novartis and Proximagen. ","March 2012","The American Journal of Psychiatry  ","Randomized Double-blind Placebo Controlled ","26 M: 11 F","20-80 mg/d; mean: 64.76 mg/d","73% White; 11% Black; 3% Asian; 5% Hispanic; 8% Other ",""
"31","Chantiluke, Kaylita","","K.R. received funding from Lilly for another project and speaker's honoraria from Lilly, Shire, Novartis and Medice. M.B. is a consultant for P1 Vital, Oxford, UK,. ","January 22, 2014","Oxford University Press","Randomized Double-blind Placebo Controlled  ","100% M","8-15 mg. Titrated to age and weight. 10-13 yrs and <30kg: 8mg, >30kg: 10mg; 14-17 yrs and <30kg: 10mg, >30kg: 15mg. ","Not reported. ","There is an inverse effect on mPFC activation between the 2 disorders, which could point to differences in baseline levels of 5-HT and seratonergic regions. "
"32","Chantiluke, Kaylita","","K.R. received funding from Lilly for another project and speaker's honoraria from Lilly, Shire, Novartis and Medice. M.B. is a consultant for P1 Vital, Oxford, UK,. ","January 22, 2014","Oxford University Press","Randomized Double-blind Placebo Controlled  ","100% M","8-15 mg. Titrated to age and weight. 10-13 yrs and <30kg: 8mg, >30kg: 10mg; 14-17 yrs and <30kg: 10mg, >30kg: 15mg. ","Not reported. ","There is an inverse effect on mPFC activation between the 2 disorders, which could point to differences in baseline levels of 5-HT and seratonergic regions. "
"33","Chantiluke, Kaylita","","K.R. received funding from Lilly for another project and speaker's honoraria from Lilly, Shire, Novartis and Medice. M.B. is a consultant for P1 Vital, Oxford, UK,. ","January 22, 2014","Oxford University Press","Randomized Double-blind Placebo Controlled  ","100% M","8-15 mg. Titrated to age and weight. 10-13 yrs and <30kg: 8mg, >30kg: 10mg; 14-17 yrs and <30kg: 10mg, >30kg: 15mg. ","Not reported. ","There is an inverse effect on mPFC activation between the 2 disorders, which could point to differences in baseline levels of 5-HT and seratonergic regions. "
"34","Chantiluke, Kaylita","","K.R. received funding from Lilly for another project and speaker's honoraria from Lilly, Shire, Novartis and Medice. M.B. is a consultant for P1 Vital, Oxford, UK,. ","January 22, 2014","Oxford University Press","Randomized Double-blind Placebo Controlled  ","100% M","8-15 mg. Titrated to age and weight. 10-13 yrs and <30kg: 8mg, >30kg: 10mg; 14-17 yrs and <30kg: 10mg, >30kg: 15mg. ","Not reported. ","There is an inverse effect on mPFC activation between the 2 disorders, which could point to differences in baseline levels of 5-HT and seratonergic regions. "
"31","Reddihough, Dinah S. ","","NHMRC, Royal Children's Hospital Foundation, Shire, Medice, Newron Pharma, Health Tracker Ltd. ","October 22, 2019 ","The Journal of the American Medical Association","Randomized Double-blind Placebo Controlled  - Multisite","85% males; 15% females ","4 or 8 mg/d for the first week, titrated to max dose of 20 or 30 mg/d","not reported ","""Interpretation is limited by the high drop out rate, null findings of prespecified analyses that accounted for potentially cofounding factors and baseline imbalances, and CIs for the treatment effect that included the minimal clinically important difference."""
"32","Reddihough, Dinah S. ","","NHMRC, Royal Children's Hospital Foundation, Shire, Medice, Newron Pharma, Health Tracker Ltd. ","October 22, 2019 ","The Journal of the American Medical Association","Randomized Double-blind Placebo Controlled  - Multisite","85% males; 15% females ","4 or 8 mg/d for the first week, titrated to max dose of 20 or 30 mg/d","not reported ","""Interpretation is limited by the high drop out rate, null findings of prespecified analyses that accounted for potentially cofounding factors and baseline imbalances, and CIs for the treatment effect that included the minimal clinically important difference."""
"33","Reddihough, Dinah S. ","","NHMRC, Royal Children's Hospital Foundation, Shire, Medice, Newron Pharma, Health Tracker Ltd. ","October 22, 2019 ","The Journal of the American Medical Association","Randomized Double-blind Placebo Controlled  - Multisite","85% males; 15% females ","4 or 8 mg/d for the first week, titrated to max dose of 20 or 30 mg/d","not reported ","""Interpretation is limited by the high drop out rate, null findings of prespecified analyses that accounted for potentially cofounding factors and baseline imbalances, and CIs for the treatment effect that included the minimal clinically important difference."""
"34","Reddihough, Dinah S. ","","NHMRC, Royal Children's Hospital Foundation, Shire, Medice, Newron Pharma, Health Tracker Ltd. ","October 22, 2019 ","The Journal of the American Medical Association","Randomized Double-blind Placebo Controlled  - Multisite","85% males; 15% females ","4 or 8 mg/d for the first week, titrated to max dose of 20 or 30 mg/d","not reported ","""Interpretation is limited by the high drop out rate, null findings of prespecified analyses that accounted for potentially cofounding factors and baseline imbalances, and CIs for the treatment effect that included the minimal clinically important difference."""
"31","Hollander, Eric","10.1038/sj.npp.1300627","No commercial affiliations","2005","Neuropsychopharmacology","RPCT - Crossover","","mean final dose: 9.9 mg/d (SD: 4.5 mg)","","https://www.nature.com/articles/1300627"
"32","Hollander, Eric","10.1038/sj.npp.1300627","No commercial affiliations","2005","Neuropsychopharmacology","RPCT - Crossover","","mean final dose: 9.9 mg/d (SD: 4.5 mg)","","https://www.nature.com/articles/1300627"
"33","Hollander, Eric","10.1038/sj.npp.1300627","No commercial affiliations","2005","Neuropsychopharmacology","RPCT - Crossover","","mean final dose: 9.9 mg/d (SD: 4.5 mg)","","https://www.nature.com/articles/1300627"
"34","Hollander, Eric","10.1038/sj.npp.1300627","No commercial affiliations","2005","Neuropsychopharmacology","RPCT - Crossover","","mean final dose: 9.9 mg/d (SD: 4.5 mg)","","https://www.nature.com/articles/1300627"
"35","McDougle, Christopher J. ","","Abraham Ribicoff Research Facilities, connecticut Mental Health Center, Yale University ","November 1996 ","Arch Gen Psychiatry ","Randomized Double-blind Placebo Controlled  ","","","",""
"36","McDougle, Christopher J. ","","Abraham Ribicoff Research Facilities, connecticut Mental Health Center, Yale University ","November 1996 ","Arch Gen Psychiatry ","Randomized Double-blind Placebo Controlled  ","","","",""
"37","McDougle, Christopher J. ","","Abraham Ribicoff Research Facilities, connecticut Mental Health Center, Yale University ","November 1996 ","Arch Gen Psychiatry ","Randomized Double-blind Placebo Controlled  ","","","",""
"35","Sugie, Yoko","10.1007/s10803-005-3305-2","","June 2005","Journal of Autism & Developmental Disorders","double-blind Randomized Double-blind Placebo Controlled  - crossover","15 M: 4 F","1 mg/kg/d for 2 weeks, 2 mg/kg/d for 3 weeks, 3 mg/kg/d for 6 weeks, 1.5 mg/kg/d for 2 weeks","",""
"36","Sugie, Yoko","10.1007/s10803-005-3305-2","","June 2005","Journal of Autism & Developmental Disorders","double-blind Randomized Double-blind Placebo Controlled  - crossover","15 M: 4 F","1 mg/kg/d for 2 weeks, 2 mg/kg/d for 3 weeks, 3 mg/kg/d for 6 weeks, 1.5 mg/kg/d for 2 weeks","",""
"37","Sugie, Yoko","10.1007/s10803-005-3305-2","","June 2005","Journal of Autism & Developmental Disorders","double-blind Randomized Double-blind Placebo Controlled  - crossover","15 M: 4 F","1 mg/kg/d for 2 weeks, 2 mg/kg/d for 3 weeks, 3 mg/kg/d for 6 weeks, 1.5 mg/kg/d for 2 weeks","",""
"35","","","","","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled - Crossover  ","15 M: 4 F","","",""
"36","","","","","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled - Crossover  ","15 M: 4 F","","",""
"37","","","","","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled - Crossover  ","15 M: 4 F","","",""
"38","Frye, RE","","EVQ and JMS are inventors in a patent for detecting of the autoantibodies described in this study issued to the Research Foundation of the SUNY. REF and EVQ are members of the advisory board to Illiad Neurosciences, Inc.","October 18, 2016","Molecular Psychiatry","Randomized Double-blind Placebo Controlled ","82% M","5, 10, or 25mg; Max: 50mg/day","Not reported ","This study suggests that FRAAs predict response to high-dose folinic acid tx. "
"39","Batebi, Neda","","No conflicts of interest.","October 7, 2020","Child Psychiatry and Human Development","Randomized Double-blind Placebo Controlled ","35 M: 20 F","Risperidone- 1-2 mg/d (Flexible based on weight). Under 20 kg max: 1 mg/d, pts 20 kgo max: 2 mg/d, + Folinic acid: 2 mg/kg/d, up to 50 mg/d; or + placebo","Not reported.","Both the folinic acid and placebo groups showed improvements in all ABC-C subscales over the course of the treatment, confirming that risperidone is beneficial in relieving ASD symptoms. "
"40","Niederhofer, H","","","2002","BMJ","Randomized Double-blind Placebo Controlled ","","","",""
"40","Ghaleiha, A","","","2014","Journal of Psychopharmacology","Randomized Double-blind Placebo Controlled ","","up to 24 mg/d","",""
"41","Hasanzadeh, Elmira","","No conflicts of interest. ","March 6, 2012","Child Psychiatry & Human Development","Randomized Double-blind Placebo Controlled  - Pilot","39 M: 8 F","Risperidone: 1-3 mg/d + Gingko: 80 mg/d (pts under 30 kg), 120 mg/d (pts 30 kg); or + placebo","Not reported. No significant demographical differences between tx groups. ",""
"42","Scahill, Lawrence","10.1176/appi.ajp.2015.15010055","Shire Pharmaceuticals provided guanfacine and placebo. Bracket, Coronado, MedAdvante, Neuren, Roche, and Shire. Seaside Therapeutics. ","August 28, 2015","The American Journal of Psychiatry  ","RCT - multisite","9 F: 53 M","1-4 mg/d; mean: 3 mg/d","30 White; 11 Black; Asian; 2 Pacific Islander; 4 Mixed",""
"43","Campbell, M","","","1982","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled ","","","","There was more of a ""positive impact on learning when haloperidol treatment was combined with language training""."
"44","Campbell, M","","","1982","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled ","","","","There was more of a ""positive impact on learning when haloperidol treatment was combined with language training""."
"43","Anderson","","","1989","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled ","","","",""
"44","Anderson","","","1989","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled ","","","",""
"45","Anagnostou, Evdokia","","Proximagen, Neuropharm, Seaside Therapeutics, and Novartis","2012","Anagnostou et al. Molecular Autism","RPCT- Pilot ","16 M: 3 F","24 IU BID","73.7% White; 5.2% Black; 5.2% Hispanic; 10.5% Asian; 5.2% Other","IN-OXT has a very short half-life in the blood. "
"46","Anagnostou, Evdokia","","Proximagen, Neuropharm, Seaside Therapeutics, and Novartis","2012","Anagnostou et al. Molecular Autism","RPCT- Pilot ","16 M: 3 F","24 IU BID","73.7% White; 5.2% Black; 5.2% Hispanic; 10.5% Asian; 5.2% Other","IN-OXT has a very short half-life in the blood. "
"45","Parker, Karen","","No conflicts of interest. ","July 25, 2017","PNAS","RPCT - Parallel design","27 M: 5 F","24 IU BID","14 white; 9 asian; 9 other",""
"46","Parker, Karen","","No conflicts of interest. ","July 25, 2017","PNAS","RPCT - Parallel design","27 M: 5 F","24 IU BID","14 white; 9 asian; 9 other",""
"47","Belsito, Karin M.","","Glaxco-Wellcome","2001","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled  - Parallel","27 M:1 F","mean: 5.0 mg/kg/d","89.5% white Lamotrigine group; 66.7% white in placebo group",""
"48","Mehrazad-Saber, Zahra","","No conflicts of interest.","January 30, 2018","Basic & Clinical Pharmacology & Toxicology","Randomized Double-blind Placebo Controlled  ","31 M: 12 F","500 mg/d","",""
"49","Wasserman. Stacy","10.1097/01.yic.0000224787.13782.0f","","November 2006","International Clinical Psychopharmacology","Randomized Double-blind Placebo Controlled ","17 M: 3 F","20-30 mg/kg/d","",""
"50","Geier, David","PMID: 21629200","No conflicts of interest","June 1, 2011","Medical Science Monitor","Randomized Double-blind Placebo Controlled  ","4 F: 23 M","50 mg L-cartinine/kg bodyweight/day","21 White; 6 'minorities'",""
"51","Thurman, Angela","","","April 2020","Journal of Neurodevelopmental Disorders","Lovastatin (RPCT) & open-label PILI","28 M: 2 F","max: 40 mg/d","24 Caucasian; 4 Hispanic; 1 African American; 1 Asian",""
"52","Loebel, Antony","","Sponsored by Sunovion Pharmaceuticals","December 11, 2015","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled  - Fixed dose","121 M: 29 F","20 mg/d or 60 mg/d","114 White; 24 Black; 10 Other",""
"53","Arnold, Eugene","","Dr. Aman and Dr. Arnold have received consulting honoraria and research support from multiple pharmaceutical companies.","2012","Journal of Child and Adolescent Psychopharmacology","Randomized Double-blind Placebo Controlled  - Pilot","17 M: 3 F","0.5 mg/d for 6 weeks - 2.5 mg for 2 weeks - then, 5 mg/d for 6 weeks.","17 White; 2 Asian; 1 other","""Mecamylamine appeared to be safe, but not very effective in autism. The suggestion of better results at lower doses and longer exposure warrants consideration for future trials. The next step would be exploration of a more specific a4b2 nAChR agonist, such as varenicline."""
"54","Hayashi, M","0.1007/s10803-021-05139-w","Nobelpharma","June 7, 2021","Journal of Autism & Developmental Disorders","RCT - Open-label","121 M: 75 F","1 mg, 4 mg, or placebo","Not reported","Study assessed efficacy of melatonin supplementation with adequate sleep hygeine. ""2 children were admitted to the hos-pital due to the abrupt deterioration of irritability�one of the aberrant behaviors of ASD�on the next day of the last medication. Hence, these episodes advert clinicians to be cautious when modi-fying the therapeutic intervention for children with ASD""."
"55","Ghaleiha, Ali","https://doi.org/10.1017/S1461145712000880","None. ","5/1/2013","International Journal of Neuropsychopharmacology","Randomized Double-blind Placebo Controlled ","23 M: 17 F","risperidone- 2 mg/d & memantine- max: 15 mg/d for pt 10-40 kg, 20 mg/d for pt 40 kgo, or + placebo","","https://academic.oup.com/ijnp/article/16/4/783/790133"
"56","Valluripalli Soorya, Latha","10.1089/cap.2021.0010","","","Journal of Child and Adolescent Psychopharmacology","RCT - pilot","","","",""
"57","Aman, Michael","","Forest/Allergan, Shire, Bristol-Myers Squibb, BioMarin pharmaceuticals. ","2015","Journal of Child and Adolescent Psychopharmacology","Randomized Double-blind Placebo Controlled  ","101 M: 20 F","3-15 mg/d (based on body weight)","99 White; 11 Asian; 4 Black; 7 Other",""
"58","Anagnastou, E","10.1001/jamapsychiatry.2016.1232","","August 2016","JAMA Psychiatry","Randomized Double-blind Placebo Controlled  ","45 M: 15 F","500 mg BID for 6-9 y (M: 1000 mg/d); 800 mg BID for 10-17 y (M:1587 mg/d)","4 Asian; 4 black or African; 50 white; 2 other/multiracial","51 participants were obese, 8 overweight, 1 normal weight. Most participants were taking aripiprazole (23) or risperidone (31). https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2546510"
"59","Aman, Michael; RUPP","","","March 29, 2005","Arch Gen Psychiatry","RPCT - Crossover","59 M: 7 F","Weight-dependent dosing -  Low dose: 2.5-5.0 mg TID; Mediium dose: 2.5-10.0 mg TID; high dose: 5.0-20.0 TID. See note for more info on dosage.","48 white; 9 black/African American; 6 Asian; 3 Hispanic or Latino","Methylphenidate dosing based on weight. The mean weight of pts was 30.4 kg (SD: 14.3 kg). Doses were administered 3 times per day (8 am, 12 pm, 4 pm). Low dose - 0.125 mg/kg, medium dose - 0.250 mg/kd, high dose - 0.500 mg/kg, per dose. ""Methylphenidate was consistently more efficacious in improving inattention, distractability, hyperactivity, and impulsivity than placebo was, as rated by the ABC hyperactivity scale... small to medium magnitude of response."""
"60","Aman, Michael; RUPP","","","March 29, 2005","Arch Gen Psychiatry","RPCT - Crossover","59 M: 7 F","Weight-dependent dosing -  Low dose: 2.5-5.0 mg TID; Mediium dose: 2.5-10.0 mg TID; high dose: 5.0-20.0 TID. See note for more info on dosage.","48 white; 9 black/African American; 6 Asian; 3 Hispanic or Latino","Methylphenidate dosing based on weight. The mean weight of pts was 30.4 kg (SD: 14.3 kg). Doses were administered 3 times per day (8 am, 12 pm, 4 pm). Low dose - 0.125 mg/kg, medium dose - 0.250 mg/kd, high dose - 0.500 mg/kg, per dose. ""Methylphenidate was consistently more efficacious in improving inattention, distractability, hyperactivity, and impulsivity than placebo was, as rated by the ABC hyperactivity scale... small to medium magnitude of response."""
"61","Aman, Michael; RUPP","","","March 29, 2005","Arch Gen Psychiatry","RPCT - Crossover","59 M: 7 F","Weight-dependent dosing -  Low dose: 2.5-5.0 mg TID; Mediium dose: 2.5-10.0 mg TID; high dose: 5.0-20.0 TID. See note for more info on dosage.","48 white; 9 black/African American; 6 Asian; 3 Hispanic or Latino","Methylphenidate dosing based on weight. The mean weight of pts was 30.4 kg (SD: 14.3 kg). Doses were administered 3 times per day (8 am, 12 pm, 4 pm). Low dose - 0.125 mg/kg, medium dose - 0.250 mg/kd, high dose - 0.500 mg/kg, per dose. ""Methylphenidate was consistently more efficacious in improving inattention, distractability, hyperactivity, and impulsivity than placebo was, as rated by the ABC hyperactivity scale... small to medium magnitude of response."""
"62","Aman, Michael; RUPP","","","March 29, 2005","Arch Gen Psychiatry","RPCT - Crossover","59 M: 7 F","Weight-dependent dosing -  Low dose: 2.5-5.0 mg TID; Mediium dose: 2.5-10.0 mg TID; high dose: 5.0-20.0 TID. See note for more info on dosage.","48 white; 9 black/African American; 6 Asian; 3 Hispanic or Latino","Methylphenidate dosing based on weight. The mean weight of pts was 30.4 kg (SD: 14.3 kg). Doses were administered 3 times per day (8 am, 12 pm, 4 pm). Low dose - 0.125 mg/kg, medium dose - 0.250 mg/kd, high dose - 0.500 mg/kg, per dose. ""Methylphenidate was consistently more efficacious in improving inattention, distractability, hyperactivity, and impulsivity than placebo was, as rated by the ABC hyperactivity scale... small to medium magnitude of response."""
"59","Handen, BL","PUBMED: 11055460","No conflicts of interest","2000","Journal of Autism & Developmental Disorders","double-blind, randomized, placebo-controlled, cross-over","10 M: 3 F","0.3 mg/kg and 0.6 mg/kg 2-3x per day","7 African American; 4 white; 2 Latino",""
"60","Handen, BL","PUBMED: 11055460","No conflicts of interest","2000","Journal of Autism & Developmental Disorders","double-blind, randomized, placebo-controlled, cross-over","10 M: 3 F","0.3 mg/kg and 0.6 mg/kg 2-3x per day","7 African American; 4 white; 2 Latino",""
"61","Handen, BL","PUBMED: 11055460","No conflicts of interest","2000","Journal of Autism & Developmental Disorders","double-blind, randomized, placebo-controlled, cross-over","10 M: 3 F","0.3 mg/kg and 0.6 mg/kg 2-3x per day","7 African American; 4 white; 2 Latino",""
"62","Handen, BL","PUBMED: 11055460","No conflicts of interest","2000","Journal of Autism & Developmental Disorders","double-blind, randomized, placebo-controlled, cross-over","10 M: 3 F","0.3 mg/kg and 0.6 mg/kg 2-3x per day","7 African American; 4 white; 2 Latino",""
"59","Pearson, DA","https://doi.org/10.1089/cap.2012.0096","The authors report having received financial support from pharmaceutical companies (including manufacturers of pharmaceuticals for behavioral syndromes)","2013","Journal of Child and Adolescent Psychopharmacology","double-blind, placebo-controlled, cross-over","19 M: 5 F","","13 white; 5 Hispanic; 4 African-American; 1 Asian; 1 multiple races",""
"60","Pearson, DA","https://doi.org/10.1089/cap.2012.0096","The authors report having received financial support from pharmaceutical companies (including manufacturers of pharmaceuticals for behavioral syndromes)","2013","Journal of Child and Adolescent Psychopharmacology","double-blind, placebo-controlled, cross-over","19 M: 5 F","","13 white; 5 Hispanic; 4 African-American; 1 Asian; 1 multiple races",""
"61","Pearson, DA","https://doi.org/10.1089/cap.2012.0096","The authors report having received financial support from pharmaceutical companies (including manufacturers of pharmaceuticals for behavioral syndromes)","2013","Journal of Child and Adolescent Psychopharmacology","double-blind, placebo-controlled, cross-over","19 M: 5 F","","13 white; 5 Hispanic; 4 African-American; 1 Asian; 1 multiple races",""
"62","Pearson, DA","https://doi.org/10.1089/cap.2012.0096","The authors report having received financial support from pharmaceutical companies (including manufacturers of pharmaceuticals for behavioral syndromes)","2013","Journal of Child and Adolescent Psychopharmacology","double-blind, placebo-controlled, cross-over","19 M: 5 F","","13 white; 5 Hispanic; 4 African-American; 1 Asian; 1 multiple races",""
"59","Quintana, H","PUBMED: 7559293","No conflicts of interest ","1995","Journal of Autism and Developmental Disorders","Double blind - crossover","6 M: 4 F","10-20 mg BID","Not reported",""
"60","Quintana, H","PUBMED: 7559293","No conflicts of interest ","1995","Journal of Autism and Developmental Disorders","Double blind - crossover","6 M: 4 F","10-20 mg BID","Not reported",""
"61","Quintana, H","PUBMED: 7559293","No conflicts of interest ","1995","Journal of Autism and Developmental Disorders","Double blind - crossover","6 M: 4 F","10-20 mg BID","Not reported",""
"62","Quintana, H","PUBMED: 7559293","No conflicts of interest ","1995","Journal of Autism and Developmental Disorders","Double blind - crossover","6 M: 4 F","10-20 mg BID","Not reported",""
"63","McDougle, Christopher J. ","","","Mar-22","Neuropsychopharmacology","RCT","","7.5-45 mg/d","",""
"64","Bernaerts, Sylvie","10.1186/s13229-020-0313-1","No conflicts of interest. ","January 15, 2020","BioMed Central","RPCT - Pilot, parallel design ","100% M","24 IU qD ","not reported","This study assesses the long-term effects of intranasal oxytocin treatment. ""Long-term beneficial effects on repetitive behaviors and feelings of avoidance are promising and suggestive of a therapeutic potential of oxytocin treatment for ASD."""
"65","Dean, Olivia ","","No conflicts of interest reported. ","June 17, 2016","Australian and New Zealand Journal of Psychiatry","RPCT, Parallel ","79 M: 19 F","500 mg/d","","Can only access the abstract, so some data is unknown. ""This study failed to demonstrate any benefit of adjunctive N-acetylcysteine in treating autistic disorder. While this may reflect a true null result, methodological issues particularly the lower dose utilised in this study may be cofounders."""
"66","Campbell, Magda","","No conflicts of interest reported. ","1993","Journal of the American Academy of Child and Adolescent Psychiatry","Randomized Double-blind Placebo Controlled ","","","","""Naltrexone does not appear to have robust effects targeting ASD-Associated aggression, although it may have some impact on hyperactivity in the population"" (Fitzpatrick)"
"67","Campbell, Magda","","No conflicts of interest reported. ","1993","Journal of the American Academy of Child and Adolescent Psychiatry","Randomized Double-blind Placebo Controlled ","","","","""Naltrexone does not appear to have robust effects targeting ASD-Associated aggression, although it may have some impact on hyperactivity in the population"" (Fitzpatrick)"
"66","Campbell, Magda","","","","Journal of the American Academy of Child and Adolescent Psychiatry ","Randomized Double-blind Placebo Controlled ","21 M: 3 F","1.0 mg/kg/d","21 white; 3 African-American (""Race was not associated with socioeconomic status in this sample.""",""
"67","Campbell, Magda","","","","Journal of the American Academy of Child and Adolescent Psychiatry ","Randomized Double-blind Placebo Controlled ","21 M: 3 F","1.0 mg/kg/d","21 white; 3 African-American (""Race was not associated with socioeconomic status in this sample.""",""
"68","Hollander, Eric","","","2006","Journal of Child and Adolescent Psychopharmacology","Randomized Double-blind Placebo Controlled   - Pilot","","7.5-12.5 mg/d; mean: 10 (SD: 2.4 mg/d)","","Very small treatment group."
"69","Bent, Stephen","","No conflicts of interest reported. ","August 4, 2010","Springer Link","Randomized Double-blind Placebo Controlled  ","Not reported. ","1.3 g/d","Not reported. ",""
"70","Hardan, Antonio","10.1016/j.biopsych.2012.01.014.","Bristol-Myers Squibb Co., Forest Pharmaceuticals, Shire Development, Inc. and Bioadvantex, Inc. ","June 1, 2012","Biological Psychiatry ","RPCT, Pilot","31 M: 2 F","max: 2700mg/d; 900mg/d for the first 4 weeks, 900mg BID  for the next 4 weeks; 900mg 3x/day for the remainder.  ","""There were no differences between the placebo group and active group on any of the demographic and clinical baseline measures.""",""
"71","Sikich, Linmarie","10.1056/NEJMoa2103583","No conflcits of interest","October 2021","The New England Journal of Medicine","RCT","142 M: 35 F","48 IU-80 IU daily; mean maximal daily dose: 69 SD: 16.9 IU","204 white; 23 black; 23 Asian; 23 multiracial; 28 Hispanic","Flexible dose strategy used could be a limitation"
"72","Yamasue, Hidenori","10.1038/s41380-018-0097-2","","2020","Molecular Psychiatry","Randomized Double-blind Placebo Controlled  ","","48 IU/d","",""
"73","Akhondzadeh, Shahin","","","2009","Progress in Neuro-Psychopharmacology and Biological Psychiatry","Randomized Double-blind Placebo Controlled ","","Risperidone- 3 mg/d + pentoxifylline- 600 mg/d, or + placebo","","https://www.sciencedirect.com/science/article/abs/pii/S0278584609003091"
"74","Akhondzadeh, Shahin","","None reported. ","October 11, 2007","Child Psychiatry and Human Development","Randomized Double-blind Placebo Controlled  ","30 M: 10 F","Risperidone: 2 mg/d for children 10-40 kg; 3 mg/d for children 40 kgo; Piracetam: up to 800 mg/d","Not reported.","Risperidone adjuvant piracetam proved to show markedly greater improvements in ASD symptoms than risperidone by itself. ""The results suggest that a combination of atypical antipsychotic medications and a glutamate agent such as piracetam, might have increase synergistic effects..."" when treating disruptive symptoms in ASD. "
"75","Grimaldi, R.","https://doi.org/10.1186/s40168-018-0523-3","Clasado Research Services Ltd (provided prebiotic and funding)","2018","Microbiome","RCT","31 M: 10 F","prebiotic B-GOS mixture (Bimuno, 80% GOS content): 1.8 g, and exclusion dieet (gluten and casein free)","Not reported","Four arm trial - exclusion diet + B-GOS, exclusion diet + placebo, unrestricted diet + B-GOS, unrestricted diet + placebo"
"76","Arnold, Eugene ","","","November 9, 2019","Journal of Child and Adolescent Psychopharmacology","RPCT - Pilot ","","","",""
"79","Arnold, Eugene ","","","November 9, 2019","Journal of Child and Adolescent Psychopharmacology","RPCT - Pilot ","","","",""
"77","Arnold, Eugene","","","2019","Journal of Child and Adolescent Psychopharmacology","RPCT- Pilot","6 M: 4 F","","5 Black; 3 white; 2 other/multiracial",""
"78","Arnold, Eugene","","","2019","Journal of Child and Adolescent Psychopharmacology","RPCT- Pilot","6 M: 4 F","","5 Black; 3 white; 2 other/multiracial",""
"77","Santocchi, Elisa","https://doi.org/10.3389/fpsyt.2020.550593","","September 2020","Frontiers in Psychiatry","RCT","84% M","2 packets/day in first month, then 1 packet/day for the remainder","",""
"78","Santocchi, Elisa","https://doi.org/10.3389/fpsyt.2020.550593","","September 2020","Frontiers in Psychiatry","RCT","84% M","2 packets/day in first month, then 1 packet/day for the remainder","",""
"76","Parracho","","","2010","","RCT - crossover","","L. plantarum WCFSI 45 billion CFU/capsule","",""
"79","Parracho","","","2010","","RCT - crossover","","L. plantarum WCFSI 45 billion CFU/capsule","",""
"80","Liu, Yen-Wenn","10.3390/nu11040820","Bened Biomedical Co., Ltd.","April 2019","Nutrients","RCT","All male","3 x 10^10 CFU/capsule of PS128","",""
"81","Schroder, Carmen M.","10.1089/cap.2018.0020","","May 11, 2019","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled  ","92 M: 33 F","2-5 mg","112 white; 9 black or african american; 6 other; 2 Asian","""PedPRM alleviates insomnia related difficulties, particularly externalizing behavior in the children, subsequently improving caregivers' quality of life."" "
"82","Gringras, Paul","","Neurim Pharmaceuticals, Akili, Alcobra, KemPharm, Pfizer, Purdue, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals, Syneurx, Takeda, Teva, Touchpoint, Tris, Validus, and WebMD","November 2017","Journal of the American Academy of Child and Adolescent Psychiatry ","Randomized Double-blind Placebo Controlled  ","92 M: 33 F","2-5 mg","112 white; 9 black; 2 Asian; 6 other",""
"83","Williams, Daniel T. ","","Not reported","1982","Journal of the American Academy of Child and Adolescent Psychiatry","Retrospective study","26 M: 4 F","50-960 mg/d; mean: 160 mg/d","",""
"84","Ameis, Stephanie","doi:10.1016/j.brs.2020.01.007.","Brainsway Ltd","2020","Brain Stimulation","RCT - sham controlled","28 M: 12 F","20 Hz rTMS targeting DLPFC","",""
"85","Ameis, Stephanie","","No conflicts of interest. ","2017","Journal of Child and Adolescent Psychopharmacology","Randomized Double-blind Placebo Controlled  ","Not reported. ","20 Hz rTMS applied to dorsolateral prefontal cortex","","All psychiatric medications were continued throughout trial. "
"86","Hendouei, Fatemeh","10.1111/jcpt.13076","No conflicts of interest","2020","Journal of Clinical Pharmacy and Therapeutics","Randomized Double-blind Placebo Controlled ","50 M: 12 F","risperidone: and resveratrol: 250 mg BID, or plus placebo","Not reported",""
"87","Wink, Logan K.","","No conflicts of interest. ","Aprill 11, 2018","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled   - Crossover","7 M:1 F","200 mg/d","5 white; 1 African-American; 1 hispanic",""
"88","Ghaleiha, Ali","","No conflicts of interest or commercial funding.","July 3, 2013","Pediatric Drugs","Randomized Double-blind Placebo Controlled ","33 M: 7 F","Risperidone- 2 or 3 mg/d (both based on body weight) + Riluzole- 50 or 100 mg/d; or + placebo","Not reported. No significant differences between tx group baseline characteristics.","""...Significance was reached on the irritability and hyperactivity/noncompliance subscales scores by the middle of the trial, suggesting an early impact of riluzole on behavioral disturbances. This finding is congruent with the formerly evident concept that pharmacological treatments are more efficient in ameliorating comorbid symptoms than in ameliorating core deficits in patients with autism"". "
"89","Aman, Michael","10.1089/cap.2007.0133","Affiliations with Bristol-Meyers Squibb Co, Johnson and Johnson, Forest Research Institute, Neuropharm, Supernus, Novartis, Organon, Janssen, and McNeil.","2008","Journal of Child and Adolescent Psychopharmacology","Randomized Double-blind Placebo Controlled ","9 F: 29 M","0.5-3.5 mg/d","81.57% White; 5.26% Black; 7.89% Asian/Pacific Islander; 5.26% Hispanic","Affiliations with Janssen, who manufactures risperidone and is also the company who assigned the drug order."
"89","Kent, Justine","10.1007/s10803-012-1723-5","Janssen, Bristol-Myers Squibb, Pfizer, Purdue Pharma, Forest","December 2012","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled ","","low dose: 0.125�mg/d [20 to <45�kg], 0.175�mg/d [>45�kg]; or high-dose: 1.25�mg/day [20 to <45�kg], 1.75�mg/day [>45�kg]) or placebo","",""
"90","McCracken, James ","","No conflicts of interest. ","August 1, 2002","The New England Journal of Medicine","Randomized Double-blind Placebo Controlled ","82 M: 19 F","0.5-3.5 mg/d; Mean: 1.8 mg/d","Not reported. "," "
"91","Ghanizadeh, Ahmad","","","January 2015","Pediatric Neurology","Randomized Double-blind Placebo Controlled ","","Buspirone: 10 mg/d for pts under 40 kg, and 20 mg/d for pts 40 kgo; Risperidone: 2 mg/d for pts under 40 kg, and 3 mg/d for pts 40 kgo","","""Buspirone may be considered for children with SIBs who have concomitant anxiety."" "
"92","Ghanizadeh, Ahmad","","No conflicts of interest. ","July 25, 2013","BioMed Central Psychiatry","Randomized Double-blind Placebo Controlled ","25 M: 15 F","NAC: 1200 mg/d (In 2 divided doses) + risperidone: 0.5-3 mg/d (m: 0.76), or risperidone (m: 0.92) + placebo. ","Baseline demographics not reported. ","Risperidone was flexibly dosed based on efficacy and weight. "
"93","Ghanizadeh, Ahmad","","No conflicts of interest. ","July 25, 2013","BioMed Central Psychiatry","Randomized Double-blind Placebo Controlled ","25 M: 15 F","NAC: 1200 mg/d (In 2 divided doses) + risperidone: 0.5-3 mg/d (m: 0.76), or risperidone (m: 0.92) + placebo. ","Baseline demographics not reported. ","Risperidone was flexibly dosed based on efficacy and weight. "
"92","Nikoo, Mohammadali","","No conflicts of interest. ","January 2015","Clinical Neuropharmacology","Randomized Double-blind Placebo Controlled ","","NAC: 600-900 mg/d (3 divided doses) + risperidone: 1-2 mg/d, or + placebo","Baseline characteristics were not significantly different in the participants.",""
"93","Nikoo, Mohammadali","","No conflicts of interest. ","January 2015","Clinical Neuropharmacology","Randomized Double-blind Placebo Controlled ","","NAC: 600-900 mg/d (3 divided doses) + risperidone: 1-2 mg/d, or + placebo","Baseline characteristics were not significantly different in the participants.",""
"94","Rezaei, Vala","10.1016/j.pnpbp.2010.07.005","","July 2010","Progress in Neuro-Psychopharmacology and Biological Psychiatry","Randomized Double-blind Placebo Controlled ","27 M: 13 F","Risperidone: 2 mg/d for pts under 40 kg and 3 mg/d for pt 40 kgo; Topirimate: 100 mg/d for pts under 30kg and 200 mg/d for pt 30 kgo","",""
"95","Miral, Suha","","","December 13, 2007","European Child & Adolescent Psychiatry","Randomized Double-blind Placebo Controlled  ","","0.01-0.08 mg/kg/d","",""
"96","Potter, Laura ","10.3389/fpsyt.2019.00810","No conflicts of interest. ","November 6, 2019","Frontiers in psychiatry","Randomized Double-blind Placebo Controlled  ","46 M: 12 F","2.5 mg/d for participants 4yo; 5.0 mg/d for participants 4yo ","7 Black; 11 Asian; 3 Other/unknown; 37 White","""The trial drew subjects mainly from the northern California area, out of convenience. Thus, the study sample may not be representative of the greater population of children with ASD."""
"97","Singh, Kanwaljit","","The Johns Hopkins University has applied to patent this. Not a commercial product. ","October 28, 2014","PNAS","Randomized Double-blind Placebo Controlled  ","100% M","50-150 umol","39 White; 2 Black; 1 Hispanic; 2 Asian","Limitations: the study only tested males who were primarily caucasian. ""�responses to sulforaphane in this study appeared over several weeks. This finding suggests that sulforaphane may cause increases in gene transcription in multiple underperforming cell-signaling pathways."""
"98","Klaiman, Cheryl","","Funded by Biomarin Pharmaceuticals","November 5, 2009","Journal of Child and Adolescent Psychopharmacology","Randomized Double-blind Placebo Controlled ","38 M: 8 F","20 mg/kg/d","21 White; 14 Asian-Pacific Islander; 3 African American; 1 Hispanic; 7 Other",""
"99","Qui, Jiujun","10.1155/2021/6627507","No conflict of interest","June 2021","Neural Plasticity","RCT","30 M: 10 F","tDCS over the left dorsal lateral prefrontal cortex (DLPFC) 5x/week","",""
"100","Darwish, Mohamed","","No conflicts of interest. ","June 2021","The Egyptian Journal of Otalaryngology","RCT","20 M: 10 F","Once per week over the left frontal gyrus: low frequency of 1.0 Hz and 70% of the motor threshold, total 1800 pulses per day session with 20 trains with 90 pulses each ","Not reported",""
"101","Hellings, Jessica","","","","Journal of Child and Adolescent Psychopharmacology","Randomized Double-blind Placebo Controlled ","20 M: 10 F","","27 White; 2 Black; 1 Hispanic ",""
"102","Mazahery, Hajar","","No conflicts of interest. ","January 3, 2019","Journal of Autism & Developmental Disorders","Randomized Double-blind Placebo Controlled  ","100 M: 17 F","2000 IU Vitamin D3; 722mg Omega 3- docosahexaenoic acid; both; or placebo ","57 NZ European; 15 Maori; 13 Pacific Islander; 13 Asian; 18 Others",""
"103","Carminati, Giuliana","10.1016/j.pnpbp.2015.09.002","","September 2015","Progress in Neuropsychopharmacology & Biological Psychiatry","RCT","","18.75 mg/d venlafaxine","",""
"104","Parker, Karen","10.1126/scitranslmed.aau7356.","Janssen Pharmaceuticals, Syneos Health, Saniona, Vista Point Capital, Katana Pharmaceuticals, Anatomics, Ginex Inc., Trigemina Inc. ","May 2019","Science Translational Medicine","RCT","25 M: 25 F","6-9.5 y: max: 12 IU BID; 9.6-12.9 y: 16 IU BID","19 white, 11 ""other""",""
"105","Behmanesh, Helen","DOI:�10.1097/WNF.0000000000000368","","November 2019","Clinical Neuropharmacology","RCT","","","",""
